Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.79 |
| ▸ | CKS1B | P61024 | 2/20 | 0.55 |
| ▸ | SKP1 | P63208 | 2/20 | 0.55 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.50 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | KIT | P10721 | 1/20 | 0.47 |
| ▸ | GBA1 | P04062 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3486839 | 0.89 | GPR119 (1.00) | GPR119KDM4E | |
| SCHEMBL14614610 | 0.82 | CKS1B (0.59) | GPR119CKS1BSKP1SKP2MAP4K4 | |
| SCHEMBL18701806 | 0.81 | GPR119 (0.54) | GPR119CKS1BSKP1SKP2KDM4E | |
| SCHEMBL6526705 | 0.81 | GPR119 (0.61) | GPR119KDM4E | |
| SCHEMBL1459701 | 0.81 | GPR119 (0.79) | GPR119CKS1BSKP1SKP2KDM4E | |
| SCHEMBL30516861 | 0.81 | GPR119 (0.79) | GPR119CKS1BSKP1SKP2KDM4E | |
| SCHEMBL4316079 | 0.81 | CKS1B (0.55) | GPR119CKS1BSKP1SKP2MAP4K4 | |
| SCHEMBL20469138 | 0.80 | GPR119 (0.60) | GPR119 | |
| SCHEMBL31296441 | 0.80 | CKS1B (0.55) | GPR119CKS1BSKP1SKP2MAP4K4 | |
| SCHEMBL21521592 | 0.80 | CKS1B (0.55) | GPR119CKS1BSKP1SKP2MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240270747-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | GENENTECH, INC. (US) | 2024-08-15 | — | — | US | disclosed |
| US-20230279012-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | GENENTECH, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| WO-2023139536-A1 | (4-PIPERAZIN-1YL)-4-ALKYL-PHTHALAZIN-1(2H)-ONE COMPOUNDS AS PARP7 INHIBITORS | RHIZEN PHARMACEUTICALS AG (CH) | 2023-07-27 | — | — | WO | disclosed |
| CN-107011348-B | Heteroaryl pyridone and aza-pyridone compounds as inhibitors of BTK activity | 霍夫曼-拉罗奇有限公司 | 2020-01-10 | — | — | CN | disclosed |
| EP-3241554-A1 | QUINOLINE-8-SULFONAMIDE DERIVATES HAVING AN ANTICANCER ACTIVITY | Agios Pharmaceuticals, Inc. (US) | 2017-11-08 | — | — | EP | disclosed |
| US-20170183311-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS, INC. | 2017-06-29 | — | — | US | disclosed |
| EP-2448582-B1 | QUINOLINE-8-SULFONAMIDE DERIVATIVES HAVING AN ANTICANCER ACTIVITY | AGIOS PHARMACEUTICALS INC (US) | 2017-04-19 | — | — | EP | disclosed |
| US-9353107-B2 | 3-(pyrazolyl)-1H-pyrrolo[2,3-b]pyridine derivatives as kinase inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2016-05-31 | — | — | US | disclosed |
| US-20150336949-A1 | 3-(Pyrazolyl)-1H-Pyrrolo[2,3-b]Pyridine Derivatives as Kinase Inhibitors | Um Pharmauji Sdn. Bhd. (MY) | 2015-11-26 | — | — | US | disclosed |
| EP-2867233-A1 | 3-(PYRAZOLYL)-1H-PYRROLO[2,3-b]PYRIDINE DERIVATIVES AS KINASE INHIBITORS | Aurigene Discovery Technologies Limited (IN) | 2015-05-06 | — | — | EP | disclosed |
| CN-104125959-A | Heteroaryl pyridone and aza-pyridone compounds as inhibitors of BTK activity | HOFFMANN LA ROCHE | 2014-10-29 | — | — | CN | disclosed |
| US-8785450-B2 | Therapeutic compounds and compositions | AGIOS PHARMACEUTICALS, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| WO-2014006554-A1 | 3-(PYRAZOLYL)-1H-PYRROLO[2,3-b]PYRIDINE DERIVATIVES AS KINASE INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2014-01-09 | — | — | WO | disclosed |
| US-20110301143-A1 | HETEROCYCLIC DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK CANADA INC. (CA) | 2011-12-08 | — | — | US | disclosed |
| US-20110301143-A1 | HETEROCYCLIC DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK CANADA INC. (CA) | 2011-12-08 | — | — | US | disclosed |
| US-20110301143-A1 | HETEROCYCLIC DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK CANADA INC. (CA) | 2011-12-08 | — | — | US | disclosed |
| WO-2011002817-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | WO | disclosed |
| US-20100331307-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS, INC. | 2010-12-30 | — | — | US | disclosed |
| WO-2010094126-A1 | HETEROCYCLIC DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2010-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170183311-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | PDK1, PDK2, PDK3 | GPR119 310/4885CKS1B 146/4885SKP1 769/4885 |
| US-20240270747-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | PDXK, BTK, TYK2 | GPR119 2921/4885CKS1B 264/4885SKP1 1135/4885 |
| US-20100331307-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | PDK1, PDK2, PDK3 | GPR119 310/4885CKS1B 146/4885SKP1 769/4885 |
| US-20230279012-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | PDXK, BTK, TYK2 | GPR119 2921/4885CKS1B 264/4885SKP1 1135/4885 |
| US-20110301143-A1 | HETEROCYCLIC DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | SCD, SCD5, COASY | GPR119 68/4885CKS1B 826/4885SKP1 1319/4885 |
| US-20150336949-A1 | 3-(Pyrazolyl)-1H-Pyrrolo[2,3-b]Pyridine Derivatives as Kinase Inhibitors | MAP3K3, MAP3K1, MAP3K6 | GPR119 803/4885CKS1B 102/4885SKP1 463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.